ReviewClinical and experimental medicine2026
Extracellular matrix remodeling in the pathogenesis and therapeutic strategies of rheumatoid arthritis.
Review in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Impaired telomere maintenance in rheumatoid arthritis: a case-control study of telomerase reverse transcriptase and telomeric repeat-binding factors in disease susceptibility and functional impairment.Clinical rheumatology · 2026Article
- Integrative Network Toxicology, Machine Learning, Single-Cell Analysis, scTenifoldKnk-Based Virtual Knockout, and Molecular Docking Suggest a Potential Molecular Link Between Aspartame and Rheumatoid Arthritis InvolvingInternational journal of molecular sciences · 2026Article
- Trained Immunity in Autoimmunity: Friend, Foe, or Therapeutic Target?Biomedicines · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
The pathological process of rheumatoid arthritis is not only driven by immune inflammation but is more profoundly shaped by abnormal remodeling of the extracellular matrix. This study systematically reviews the core manifestations of abnormal extracellular matrix remodeling in RA: matrix sclerosis, excessive degradation mediated by matrix metalloproteinase/a disintegrin and metalloproteinase with thrombospondin motifs, and degradation fragments as damage-associated molecular patterns activating the TLR4/RAGE pathway, thereby forming a self-perpetuating vicious cycle of "sclerosis-degradation-inflammation amplification-resclerosis," significantly exacerbating inflammatory reactions and joint damage. It proposes a dual framework of "mechanism loop-clinical loop," emphasizing the integration of the biomarkers C1M, C3M, COMP, HA, and other ECM-degradation fragments for dynamic disease monitoring, progression prediction, and precise efficacy evaluation. By combining biomarker panels with imaging data, it is expected to optimize the stratification of high-risk populations and individualized treatment adjustments, which may enhance the precision of diagnostic and therapeutic strategies and provide a new direction for RA to progress from inflammation control to structural protection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.